15/05/2024  10:47:44 Var. +3.00 Volume Denaro10:50:32 Lettera10:50:32 Capitalizzazione di mercato Dividend Y. Rapporto P/E
248.20CHF +1.22% 3,685
Fatturato: 911,177.80
248.00Quantità in denaro: 4 248.20Quantità in lettera: 136 210.45 bill.CHF 3.82% 17.25

Descrizione business

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
 

Consiglio di amministrazione & Consiglio di sorveglianza

CEO
Dr. Thomas Schinecker
Consiglio di amministrazione
Dr. Alan Hippe, Cristina A. Wilbur, Teresa Graham, Matt Sause , Claudia Bockstiegel, Prof. Dr. Hans Clevers, Dr. Levi Garraway, Silke Hornstein, Dr. Aviv Regev, Dr. James H. Sabry, Barbara Schadler
Consiglio di sorveglianza
André Hoffmann, Anita Hauser, Bernard Poussot, Dr. Claudia Süssmuth Dyckerhoff, Dr. Patrick Frost, Dr. Severin Schwan, Prof. Dr. Richard Lifton, Dr. Mark Schneider, Dr. Jemilah Mahmood, Prof. Dr. Akiko Iwasaki, Dr. Joorg Duschmale
 

Dati aziendali

Name: Roche Holding
Indirizzo: Grenzacherstraße 124,CH-4070 Basel
Telefono: +41-61-688-1111
Fax: -
E-mail: basel.webmaster@roche.com
Internet: www.roche.com
Industria: Healthcare
Settore: Pharmaceutical Industry
Sub settore: Pharmaceuticals
Fine dell'anno finanziario: 31/12
Flottante libero: 88.00%
Data dell'IPO: 03/04/1995

Rapporti con gli investitori

Name: Bruno Eschli
IR telefono: +41 (61) 687 5284
IR Fax: +41 (61) 691 0014
IR e-mail: investor.relations@roche.com

Principali azionisti

Aktionärsgruppe der Familien Hoffmann und Oeri-Hoffmann
 
67.50%
Freefloat
 
24.92%
Maja Oeri
 
7.58%